申请人:TAISHO PHARMACEUTICAL CO., LTD
公开号:EP1798226A1
公开(公告)日:2007-06-20
A compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof has an effect of inhibiting binding between SIP and its receptor Edg-1(S1P1), and is useful as a pharmaceutical product.
[where
A represents a sulfur atom, an oxygen atom, a formula -SO- or a formula -SO2-; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or the like; R2 represents an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms or the like; R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R4 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a phenyl group or the like; R5 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and R6 represents an alkyl group having 1 to 6 carbon atoms, a phenyl group or a substituted phenyl group].
下式 (I) 所代表的化合物或其药学上可接受的盐具有抑制 SIP 与其受体 Edg-1(S1P1)之间结合的作用,可用作医药产品。
其中
A 代表硫原子、氧原子、式-SO-或式-SO2-; R1 代表氢原子、具有 1 至 6 个碳原子的烷基或类似物; R2 代表具有 1 至 6 个碳原子的烷基、具有 3 至 8 个碳原子的环烷基或类似物; R3 代表氢原子或具有 1 至 6 个碳原子的烷基;R4 代表氢原子、具有 1 至 6 个碳原子的烷基、苯基或类似基团; R5 代表氢原子或具有 1 至 6 个碳原子的烷基;以及 R6 代表具有 1 至 6 个碳原子的烷基、苯基或取代苯基]。